News articles about Pharmacyclics (NASDAQ:PCYC) have trended positive on Wednesday, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pharmacyclics earned a coverage optimism score of 0.38 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.5102624730822 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

COPYRIGHT VIOLATION WARNING: This piece was first published by Marea Informative and is the sole property of of Marea Informative. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.mareainformativa.com/2018/03/14/pharmacyclics-pcyc-given-daily-news-impact-score-of-0-38-updated-updated-updated.html.

Pharmacyclics Company Profile

Pharmacyclics, Inc is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company’s commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer.

Insider Buying and Selling by Quarter for Pharmacyclics (NASDAQ:PCYC)

Receive News & Ratings for Pharmacyclics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmacyclics and related companies with MarketBeat.com's FREE daily email newsletter.